Posted by Michael Wonder on 17 Mar 2021
ICER analyses are flawed, undervalue life saving medicines, and are biased toward price controls, finds new PRI brief
17 March 2021 - A commonly-used analysis to determine a medicine's value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute.
"Cost effectiveness reports may provide precise estimates, but there is no reason to believe that these estimates accurately reflect the value of medicines," said Dr. Wayne Winegarden, the brief's author. "The documented biases in their value assessments should raise serious concerns that ICER's work is inaccurate and biased toward undervaluing medicines."
